Medtronic plc, the global leader in medical technology, today announced its participation at the 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), taking...
Medtronic plc, the global leader in medical technology, today announced its participation at the 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), taking place April 27-30, 2022. Medtronic will showcase clinically meaningful outcomes and extended study results for the MiniMed™ 780G System with Guardian™ 4 sensor, the most advanced Medtronic Advanced Hybrid Closed-Loop insulin delivery system which is currently available in 42 EMEA countries1, in addition to other research findings from the company’s comprehensive portfolio.
Scientific Presentations
The following poster and oral scientific data presentations represent the work of Medtronic employees and independent investigators using Medtronic devices in their research. Poster presentations will be available to all attendees for viewing throughout the conference.
Advanced Hybrid Closed-Loop Data Presentations
Automated Insulin Pump System Data Presentations
InPen Data Presentations
Other Data Presentations
Medtronic Sponsored Events
The following symposium will feature detailed clinical trial data and discussions with Medtronic and independent speakers. Details are as follows:
Chantal Mathieu, M.D., Ph.D. |
The current state of type 1 diabetes |
Pratik Choudhary |
The ADAPT clinical study: From failing on MDI therapy to successful outcomes with the MiniMed™ 780G system |
Tomasz Klupa, Professor, Head of the Center for Advanced Technologies in Diabetes Department and Chair of Metabolic Diseases Jagiellonian University Medical College, Poland |
Successful MiniMed™ 780G System initiation in people with Type 1 diabetes naive to technology
|
Klemen Dovc, M.D., Ph.D., Assistant Professor, Department of Pediatric Endocrinology, Diabetes and Metabolic Diseases, University Children’s Hospital, and Faculty of Medicine, University of Ljubljana, Slovenia |
First evidence with the MiniMed™ 780G system and FiAsp in adolescents: The FACT study |
Ohad Cohen, M.D., Senior Global Medical Affairs Director, Medtronic Diabetes |
Putting it all together: The MiniMed™ 780G system allowing patients to achieve 80% time in range |
Robert Vigersky, M.D. |
The need for Smart MDI system |
Rainer Strassburger-Lausen, Medical Affairs, Senior Program Manager, Medtronic Diabetes |
Smart MDI system simulation |
Rocio Harbison, M.D., Endocrinologist and Founder, Advanced Endocrinology and Diabetes Clinic, United States
|
Case presentation and experience |
Robert Vigersky, M.D. |
Clinical results: Poster/study presentation |
Ohad Cohen, M.D. |
Welcome and introduction |
Pilar Beato Vibora, M.D., Department of Paediatrics, Diabetes Technology Unit, Badajoz University Hospital |
Evidence and best practices in adults |
Henk Jan Aanstoot, M.D., Ph.D., Senior Medical Director, Diabeter, Netherlands
|
Evidence and best practices in pediatrics |
About the Diabetes Business at Medtronic (www.medtronicdiabetes.com)
Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.
1 MiniMed 780G System and Guardian™ 4 sensors are CE marked only and not commercially available or approved in the U.S.
For more information, contact:
Contacts:
Kendra Cassillo Ryan Weispfenning
Public Relations Investor Relations
+1-818-576-5611 +1-763-505-4626